Status:
COMPLETED
Acute Effect of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects
Lead Sponsor:
Regional Hospital Holstebro
Conditions:
Healthy
Eligibility:
All Genders
20-50 years
Phase:
PHASE4
Brief Summary
We wanted to test the acute effect of HMG-CoA reductase inhibition (atorvastatin) on renal hemodynamics, renal tubular function and vasoactive hormones on healthy subjects.
Eligibility Criteria
Inclusion
- Both men and women
- Age: Between 20-50
- BMI\<30
Exclusion
- Clinical signs or history of disease of heart, lungs, kidneys or endocrine organs.
- Abnormal lab. tests( haemoglobin, pl. sodium, pl. potassium, pl.creatinine, pl.bilirubin, pl.ALAT, pl. cholesterol, blood glucose)
- Albuminuria or glucosuria
- Cancer
- Art. hypertension
- Alcohol abuse
- Medical treatment, except oral contraceptives
- Pregnancy or breast feeding
- Blood donation less than 1 month before study
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
End Date :
December 1 2003
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00344955
Start Date
January 1 2003
End Date
December 1 2003
Last Update
May 15 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Research
Holstebro, Denmark, 7500